These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32135539)

  • 1. Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease.
    Kang MK; Kim KO; Kim MC; Park JG; Jang BI
    Dig Dis; 2020; 38(6):507-514. PubMed ID: 32135539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA.
    Wijarnpreecha K; Kim D; Raymond P; Scribani M; Ahmed A
    Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1121-1128. PubMed ID: 30888971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors.
    Principi M; Iannone A; Losurdo G; Mangia M; Shahini E; Albano F; Rizzi SF; La Fortezza RF; Lovero R; Contaldo A; Barone M; Leandro G; Ierardi E; Di Leo A
    Inflamm Bowel Dis; 2018 Jun; 24(7):1589-1596. PubMed ID: 29688336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease.
    Bosch DE; Yeh MM
    Hum Pathol; 2017 Nov; 69():55-62. PubMed ID: 28970141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history.
    Magrì S; Paduano D; Chicco F; Cingolani A; Farris C; Delogu G; Tumbarello F; Lai M; Melis A; Casula L; Fantini MC; Usai P
    World J Gastroenterol; 2019 Oct; 25(37):5676-5686. PubMed ID: 31602167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of sarcopenia in inflammatory bowel disease.
    Fatani H; Olaru A; Stevenson R; Alharazi W; Jafer A; Atherton P; Brook M; Moran G
    Clin Nutr; 2023 Aug; 42(8):1276-1291. PubMed ID: 37352818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.
    Saroli Palumbo C; Restellini S; Chao CY; Aruljothy A; Lemieux C; Wild G; Afif W; Lakatos PL; Bitton A; Cocciolillo S; Ghali P; Bessissow T; Sebastiani G
    Inflamm Bowel Dis; 2019 Jan; 25(1):124-133. PubMed ID: 29889226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study.
    Abenavoli L; Spagnuolo R; Scarlata GGM; Scarpellini E; Boccuto L; Luzza F
    Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38003983
    [No Abstract]   [Full Text] [Related]  

  • 9. Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease.
    Zou ZY; Shen B; Fan JG
    Inflamm Bowel Dis; 2019 Oct; 25(11):1764-1772. PubMed ID: 30918952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-Related Decrease in Skeletal Muscle Mass Is an Independent Risk Factor for Incident Nonalcoholic Fatty Liver Disease: A 10-Year Retrospective Cohort Study.
    Lee MJ; Kim EH; Bae SJ; Kim GA; Park SW; Choe J; Jung CH; Lee WJ; Kim HK
    Gut Liver; 2019 Jan; 13(1):67-76. PubMed ID: 30037166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low skeletal muscle mass is associated with non-alcoholic fatty liver disease in Korean adults: the Fifth Korea National Health and Nutrition Examination Survey.
    Kim HY; Kim CW; Park CH; Choi JY; Han K; Merchant AT; Park YM
    Hepatobiliary Pancreat Dis Int; 2016 Feb; 15(1):39-47. PubMed ID: 26818542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis.
    Noorian S; Jeon Y; Nguyen MT; Sauk J; Limketkai BN
    Inflamm Bowel Dis; 2022 Jun; 28(6):878-887. PubMed ID: 34374782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
    Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
    Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk.
    Han E; Lee YH; Kim YD; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Han KH; Nam HS; Heo JH; Kim SU
    Am J Gastroenterol; 2020 Apr; 115(4):584-595. PubMed ID: 32141917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients.
    Carr RM; Patel A; Bownik H; Oranu A; Kerner C; Praestgaard A; Forde KA; Reddy KR; Lichtenstein GR
    Dig Dis Sci; 2017 May; 62(5):1354-1361. PubMed ID: 28265826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Lin A; Roth H; Anyane-Yeboa A; Rubin DT; Paul S
    Inflamm Bowel Dis; 2021 May; 27(6):947-955. PubMed ID: 32780094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study.
    Yen HH; Su PY; Huang SP; Wu L; Hsu TC; Zeng YH; Chen YY
    PLoS One; 2021; 16(5):e0252286. PubMed ID: 34043691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Relationship between NAFLD and Sarcopenia in Elderly Patients.
    Zhai Y; Xiao Q; Miao J
    Can J Gastroenterol Hepatol; 2018; 2018():5016091. PubMed ID: 29785395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease.
    Glassner K; Malaty HM; Abraham BP
    Inflamm Bowel Dis; 2017 Jun; 23(6):998-1003. PubMed ID: 28511199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis.
    Lapumnuaypol K; Kanjanahattakij N; Pisarcik D; Thongprayoon C; Wijarnpreecha K; Cheungpasitporn W
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):854-860. PubMed ID: 29697458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.